Cargando…

Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

Purpose: With the widespread use of immunotherapy agents, we encounter treatment responses such as hyperprogression disease (HPD) that we have not seen with previous standard chemotherapy and targeted therapies. It is known that survival in patients with HPD is shorter than in patients without HPD....

Descripción completa

Detalles Bibliográficos
Autores principales:	Yildirim, Hasan Cagri, Guven, Deniz Can, Aktepe, Oktay Halit, Taban, Hakan, Yilmaz, Feride, Yasar, Serkan, Aksoy, Sercan, Erman, Mustafa, Kilickap, Saadettin, Yalcin, Suayib
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457309/ https://www.ncbi.nlm.nih.gov/pubmed/36079101 http://dx.doi.org/10.3390/jcm11175171

Ejemplares similares

The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
por: Guven, Deniz Can, et al.
Publicado: (2022)

Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19
por: Guven, Deniz Can, et al.
Publicado: (2020)

Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report
por: Taban, Hakan, et al.
Publicado: (2022)

The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma
por: AKTEPE1, Oktay Halit, et al.
Publicado: (2021)

Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
por: Akyildiz, Arif, et al.
Publicado: (2023)

The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study
por: GÜVEN, Deniz Can, et al.
Publicado: (2021)

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis
por: Guven, Deniz Can, et al.
Publicado: (2022)

Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience
por: Demir, Metin, et al.
Publicado: (2022)

Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor-kappa B (NF-κB) pathway
por: AKTEPE, Oktay Halit, et al.
Publicado: (2021)

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
por: Ismayilov, Rashad, et al.
Publicado: (2022)

1763P Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days
por: Aktas, B.Y., et al.
Publicado: (2020)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
por: Yıldırım, Hasan Çağrı, et al.
Publicado: (2022)

Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival
por: Turkoz, Fatma Paksoy, et al.
Publicado: (2014)

The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Guven, Deniz Can, et al.
Publicado: (2022)

The Prognostic Significance of KIAA1522 Expression in Non-Small-Cell Lung Cancer Patients
por: Özdede, Murat, et al.
Publicado: (2023)

Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department
por: Öcal, Osman, et al.
Publicado: (2021)

Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
por: Guven, Deniz C., et al.
Publicado: (2021)

Laryngeal Involvement of Rhabdomyosarcoma in an Adult
por: Abali, Hüseyin, et al.
Publicado: (2003)

Reproductive cancer risk factors among relatives of cancer patients in a tertiary oncology center
por: Atta, Nooria, et al.
Publicado: (2019)

Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
por: Yalcin, Suayib, et al.
Publicado: (2020)

Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review
por: Yigit, Ecem, et al.
Publicado: (2021)

Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
por: Aktaş, Burak Yasin, et al.
Publicado: (2023)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Complete response in a frail patient with high-grade B-cell lymphoma to only one cycle of R-CHOP or to prolonged COVID-19?
por: Yilmaz, Feride, et al.
Publicado: (2021)

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Artificial intelligence method to predict overall survival of hepatocellular carcinoma
por: Simsek, Cem, et al.
Publicado: (2021)

The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients
por: Ozdemir, Nesligul, et al.
Publicado: (2021)

Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
por: Carloni, Riccardo, et al.
Publicado: (2022)

Treatment delays and in-hospital outcomes in acute myocardial infarction during the COVID-19 pandemic: A nationwide study
por: Erol, Mustafa Kemal, et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
por: GÜRLER, Fatih, et al.
Publicado: (2022)

The Effect of Inferior Oblique Muscle Z-Myotomy in Patients with Primary Inferior Oblique Overaction
por: Kızıltoprak, Hasan, et al.
Publicado: (2020)

Hyperprogression: A novel response pattern under immunotherapy
por: Han, Xue‐jiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4om873ehpdke27tfo8d49dnnr